Biotec.Bk
BIOTEC.BK operates in the Marine Port Services industry, providing transportation and logistics services, primarily generating revenue through port operations and related maritime activities.
Business. BIOTEC.BK operates in the Marine Port Services industry, providing transportation and logistics services, primarily generating revenue through port operations and related maritime activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BIOTEC.BK operates in the Marine Port Services industry, providing transportation and logistics services, primarily generating revenue through port operations and related maritime activities.
BIOTEC.BK maintains a market price of 0.29 THB per share, with a market capitalization of 885.5 million THB. The company's price-to-earnings ratio is 30.2, and its price-to-book ratio is 0.81, indicating a relatively low valuation compared to book value. The enterprise value to EBITDA ratio is 15.67, and the enterprise value to revenue ratio is 0.29, suggesting a modest valuation relative to revenue.
The company's profitability metrics show a return on equity of 2.67% and a return on assets of 1.3%, both below the typical thresholds for strong performance in the Marine Port Services industry. The operating margin is 1.87%, and the net profit margin is 0.7%, indicating that the company is generating relatively low returns on its operations.
BIOTEC.BK's revenue is primarily concentrated in its core port operations, with no significant diversification across business segments. The company's geographic exposure is primarily within its domestic market, with no disclosed international operations. This concentration may increase its vulnerability to local economic conditions.
The company's growth trajectory is modest, with a current fiscal year outlook showing a revenue increase of 2.5% and a net income increase of 1.2%. The next fiscal year is projected to see a revenue increase of 3.0% and a net income increase of 1.5%. These figures suggest a slow but steady growth pattern.
The company faces a medium liquidity risk, as indicated by a current ratio of 0.57, which is below the industry median. The debt-to-equity ratio is 0.41, suggesting a moderate level of leverage. The risk assessment also notes that net cash is negative after subtracting total debt, indicating potential liquidity constraints.
Recent filings and transcripts indicate that the company is focused on maintaining operational efficiency and exploring new market opportunities. The company has not disclosed any major capital projects or strategic acquisitions in the near term. The most recent 10-K filing highlights the importance of regulatory compliance and the potential impact of geopolitical factors on its operations.
- BIOTEC.BK is undervalued relative to book value, with a price-to-book ratio of 0.81.
- The company's profitability metrics are below industry norms, with a return on equity of 2.67%.
- Revenue and net income growth are projected to be modest, with increases of 2.5% and 1.2% in the current fiscal year.
- The company faces medium liquidity risk, with a current ratio of 0.57 and a negative net cash position after debt.
- BIOTEC.BK's operations are concentrated in its domestic market, with no significant international exposure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- BIOTEC.BK Market data — financials · 2026-05-27